Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 48 (10), 1128-35

Multi-center Randomized Controlled Study to Establish the Standard Third-Line Regimen for Helicobacter Pylori Eradication in Japan

Affiliations
Randomized Controlled Trial

Multi-center Randomized Controlled Study to Establish the Standard Third-Line Regimen for Helicobacter Pylori Eradication in Japan

Kazunari Murakami et al. J Gastroenterol.

Abstract

Backgrounds: The present study sought to establish a standard third-line eradication regimen for Helicobacter pylori in Japan.

Methods: Subjects were 204 patients with H. pylori infection in whom the standard Japanese first- and second-line eradication therapies had proven unsuccessful. Patients were randomly assigned to one of the following third-line eradication therapy groups: (1) LA group: lansoprazole (LPZ) 30 mg 4 times a day (qid) + amoxicillin (AMPC) 500 mg qid for two weeks; (2) LAL group: LPZ 30 mg twice a day (bid) + AMPC 750 mg bid + levofloxacin (LVFX) 300 mg bid for one week; (3) LAS group: LPZ 30 mg bid + AMPC 750 mg bid + sitafloxacin (STFX) 100 mg bid for one week. Patients for whom these therapies failed underwent a crossover fourth-line eradication regimen. Drug sensitivity was also tested for AMPC, clarithromycin (CAM), MNZ, LVFX, and STFX.

Results: Drug resistance rates prior to third-line eradication therapy were 86.4 % for CAM, 71.3 % for MNZ, 57.0 % for LVFX, 8.2 % for AMPC, and 7.7 % for STFX. Intention-to-treat analysis of third-line eradication therapy eradication rates showed a significantly higher rate in the LAS group (70.0 %) compared with the LA group (54.3 %; p < 0.05) and the LAL group (43.1 %; p < 0.001). The significantly lower rate in the LAL group than the LAS group was caused by bacterial resistance to LVFX.

Conclusions: The findings suggest that triple therapy with PPI, AMPC, and STFX for one week would be an effective standard third-line eradication regimen for H. pylori in Japan.

Similar articles

See all similar articles

Cited by 29 PubMed Central articles

See all "Cited by" articles

References

    1. J Gastroenterol. 2004 Oct;39(10):927-30 - PubMed
    1. Helicobacter. 2006 Jun;11(3):152-8 - PubMed
    1. Helicobacter. 2001 Sep;6(3):254-61 - PubMed
    1. Antimicrob Agents Chemother. 2009 Apr;53(4):1720-1 - PubMed
    1. Helicobacter. 2006 Aug;11(4):243-9 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback